NAPLEX Diabetes Questions: Insulin-Pen Safety Cases

Which insulin-pen details does the question actually provide?

For insulin-pen cases, verify the exact name, strength, presentation, supplies, and device instructions: FDA's pen-injector teaching identifies product and strength mix-ups and product-specific technique errors. APIDRA labeling also explicitly prohibits sharing a SoloStar pen between patients, even after changing the needle.

The FDA material and APIDRA label were checked November 5, 2026; the label was revised May 2025. These sources support a focused product-verification exercise. They do not establish a complete diabetes treatment syllabus or tell you how many insulin questions will appear on your exam.

NABP's content outline, effective May 1, 2025 and checked November 3, 2026, includes order interpretation, dosage forms, storage and disposal, education, and devices. Use the NAPLEX blueprint guide to place these tasks within the broader exam.

The cases below are fictional Passy teaching exercises, not actual NABP items or instructions for administering insulin. For each, write one requested decision, identify the supplied evidence, and separate that evidence from your assumptions. This study method is editorial; NABP does not prescribe this worksheet.

How do you spot a product or strength mismatch?

Case 1: An order in a practice exercise specifies APIDRA SoloStar U-100. The selected carton resembles the expected pen packaging, but its printed product name differs. In a second version, the name appears to match while the strength printed in the exercise differs from the order. Both mismatches are fictional; neither identifies an acceptable substitute.

The APIDRA label identifies insulin glulisine U-100 as 100 units/mL. Its presentations include a 3-mL single-patient-use SoloStar prefilled pen and a 10-mL multiple-dose vial. The concentration and presentation are separate details to verify.

• Requested decision: Does the selected item match the supplied order?
• Supplied evidence: The order names the product, SoloStar presentation, and U-100 strength; the selected carton contains a conflicting field.
• Unsafe inference: Similar packaging, familiar color, or a recognizable pen shape establishes a match.
• Correct verification: Compare the exact name and strength on both pen and carton with the order, then verify the presentation. FDA notes that the product may need to be rotated to see its identifying information.
• Remaining limit: Finding a mismatch does not authorize choosing a substitute, converting a dose, or treating vial and pen instructions as interchangeable.

Your answer can be precise: “The carton conflicts with the order; resolve the product or strength discrepancy before accepting this selection.” A calculation cannot fix an unresolved identity problem. For broader source-selection decisions, continue with the NAPLEX medication-use process guide.

For practice across the wider outline, full NAPLEX prep planned for launch includes 825 questions across five content domains. Keep product identification as a separate checkpoint in your own case notes.

Does replacing the needle make sharing a pen acceptable?

Case 2: A fictional learner proposes using one person's APIDRA SoloStar pen for a second person. The learner argues that replacing the needle resolves the concern. The question asks whether that proposal agrees with the product labeling.

• Requested decision: Is the proposed sharing permitted by the label?
• Supplied evidence: This is an APIDRA SoloStar pen already used for another person; the proposed change is a new needle.
• Unsafe inference: The needle alone determines whether the device can be used for someone else.
• Correct verification: Apply the label's explicit no-sharing instruction. SoloStar is a single-patient-use pen, and replacing the needle does not remove that restriction.
• Remaining limit: This answers the sharing question. It does not establish an insulin choice, dose, or complete administration plan for either person.

The wording matters: the pen is single-patient-use. An answer that discusses only a fresh needle leaves the decisive instruction unanswered. Record the product and label rule together, then explain why the learner's proposed modification does not change the answer.

What must you check when a dispensing bundle lacks supplies?

Case 3: A fictional dispensing bundle contains the ordered pen carton but no separately listed needles. The exercise does not state whether needles are inside the carton. It asks which check is missing before calling the bundle complete.

• Requested decision: Is there enough information to confirm the required supplies?
• Supplied evidence: A pen carton is present; needle inclusion is unconfirmed.
• Unsafe inference: Every pen carton includes needles, or a familiar brand's contents establish what this carton contains.
• Correct verification: Check the exact carton and labeling for needle inclusion, then identify the supplies required by that product's instructions. FDA specifically highlights checking whether needles are included.
• Remaining limit: The exercise does not identify the appropriate supplies or establish that the bundle is ready. It identifies the information you must obtain.

Missing information is not proof that the supplies are present or absent. Write “needle inclusion unverified” and name the source that would resolve it. Do not invent a workaround using the pen as a vial; FDA includes that practice among its pen-related error categories.

For recall practice alongside source reading, full NAPLEX prep planned for launch includes 580 flashcards. In your own notes, pair each remembered rule with the product detail that makes it applicable.

Can instructions or discard periods be carried over from another pen?

Case 4: In a fictional counseling exercise, a patient says, “I used a different pen before, so I will use the same technique and discard it after the same number of days.” No instructions or in-use limit for the new product are supplied.

• Requested decision: Does experience with the previous pen establish the new product's instructions?
• Supplied evidence: The product has changed; the proposed technique and discard period come from another pen.
• Unsafe inference: All pens operate alike and share one permitted in-use period.
• Correct verification: Retrieve the exact new product and presentation's administration, storage, and disposal instructions. For the use-period question, establish the opening date, relevant conditions, and the product's labeled limit.
• Remaining limit: Without those details, the exercise cannot establish a discard date or confirm a technique.

FDA emphasizes product-specific instructions because pen designs differ and use beyond the permitted period is an error category. There is no universal storage-day number in this exercise. Learning a number without retaining its product and conditions would recreate the assumption the case asks you to identify.

If a different question turns on patient history or monitoring, use the NAPLEX patient-case method to organize that information. Here, the immediate task is to select the correct product instructions.

How do you build a product-specific verification checklist?

Use this editorial worksheet for your next practice case. Enter “not supplied” wherever the prompt leaves a gap; do not fill it with a remembered detail from another product.

Fresh practice: A fictional order, carton, and pen all match on name, strength, and presentation. The learner concludes that the dispensing bundle must therefore contain every required supply. Is that conclusion established?

Answer: No. Identity matching resolves the identity check. Needle inclusion and required supplies still need their own product-specific verification. A complete answer names that remaining gap without inventing the contents of the carton.

Start further review with the 20 free NAPLEX practice questions and the free NAPLEX study plan. Keep your case-review notes separate from official result interpretation, covered in the NAPLEX pass rates and passing-score guide.

For a longer practice session, full NAPLEX prep planned for launch includes a 225-question mock exam. Your next step is to finish one worksheet and explain exactly which fact resolves the question and which check remains open.

<!-- Writer self-check completed November 5, 2026. Claims checked against RESEARCH.md S15, A05, A06, and the per-slug claim map; product statements checked against CONTEXT.md and exam.json. Four cases, the fresh exercise, and worksheet are explicitly fictional/editorial. No regimen selection, conversion, operating procedure, universal storage period, clinical outcome, insulin item-frequency claim, or unverified feature is asserted. This PLAN entry has no assigned yearFocus; the four existing 2027 assignments are unchanged. Template, source URLs, uniqueness, links, and SEO checked. Independent review remains required. -->